- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Joined Cases C-271/14 and C-273/14: Judgment of the Court (Eighth Chamber) of 16 April 2015 (request for a preliminary ruling from the Conseil d’État (France)) — LFB Biomédicaments SA, Association des déficitaires en Alpha 1 Antitrypsine (Association ADAAT Alpha 1-France) (C-271/14), Pierre Fabre Médicament SA (C-273/14) v Ministre des Finances et des Comptes publics, Ministre des Affaires sociales et de la Santé (Reference for a preliminary ruling — Medicinal products for human use — Directive 89/105/EEC — Article 6(3) and (5) — Removal of medicinal products from a list of pharmaceutical proprietary products covered in addition to fixed payments in respect of hospital treatment — Obligation to state reasons)
ECLI:EU:UNKNOWN:62014CA0271
62014CA0271
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
C 198/14
(Joined Cases C-271/14 and C-273/14) (<span class="super">1</span>)
((Reference for a preliminary ruling - Medicinal products for human use - Directive 89/105/EEC - Article 6(3) and (5) - Removal of medicinal products from a list of pharmaceutical proprietary products covered in addition to fixed payments in respect of hospital treatment - Obligation to state reasons))
(2015/C 198/18)
Language of the case: French
Referring court
Parties to the main proceedings
Applicants: LFB Biomédicaments SA, Association des déficitaires en Alpha 1 Antitrypsine (Association ADAAT Alpha 1-France) (C-271/14), Pierre Fabre Médicament SA (C-273/14)
Defendants: Ministre des Finances et des Comptes publics, Ministre des Affaires sociales et de la Santé
Operative part of the judgment
Article 6 of Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems must be interpreted as meaning that the obligation to state reasons provided for in Article 6(3) and (5) is applicable to a decision which restricts the conditions of reimbursement or reduces the level of coverage of a medicinal product by excluding it from the list of proprietary medicinal products covered by compulsory health insurance schemes in addition to services relating to hospital treatment covered by fixed payments in respect of periods of hospitalisation and hospital care.
(<span class="super">1</span>) OJ C 282, 25.8.2014.
* * *